WHO ICTRP trial
Treatment of locally recurrent nasopharyngeal carcinoma with Camrelizumab…
ChiCTR2000035803 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2000035803 |
|---|---|
| Public title | Treatment of locally recurrent nasopharyngeal carcinoma with Camrelizumab combined with chemoradiotherapy: a prospective, randomized, controlled phase II clinical study |
| Scientific title | Treatment of locally recurrent nasopharyngeal carcinoma with Camrelizumab combined with chemoradiotherapy: a prospective, randomized, controlled phase II clinical study |
| Primary sponsor | Fudan University Shanghai Cancer Center |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | 2 |
| Countries | China |
| Conditions | nasopharyngeal carcinoma |
| Interventions | Treatment group:Camrelizumab and chemoradiotherapy;Control group:chemoradiotherapy |
| Registration date | Aug 17, 2020 |
| Target size | Treatment group:40;Control group:40 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: